Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 1
2020 3
2021 2
2022 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean brilla, c[Author] (75 results)?
Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors.
Decary S, Berne PF, Nicolazzi C, Lefebvre AM, Dabdoubi T, Cameron B, Rival P, Devaud C, Prades C, Bouchard H, Cassé A, Henry C, Amara C, Brillac C, Ferrari P, Maçon L, Lacoste E, Combeau C, Beys E, Naimi S, García-Echeverría C, Mayaux JF, Blanc V. Decary S, et al. Among authors: brillac c. Clin Cancer Res. 2020 Dec 15;26(24):6589-6599. doi: 10.1158/1078-0432.CCR-19-4051. Epub 2020 Oct 12. Clin Cancer Res. 2020. PMID: 33046521
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.
Mikhael J, Belhadj-Merzoug K, Hulin C, Vincent L, Moreau P, Gasparetto C, Pour L, Spicka I, Vij R, Zonder J, Atanackovic D, Gabrail N, Martin TG, Perrot A, Bensfia S, Weng Q, Brillac C, Semiond D, Macé S, Corzo KP, Leleu X. Mikhael J, et al. Among authors: brillac c. Blood Cancer J. 2021 May 12;11(5):89. doi: 10.1038/s41408-021-00478-4. Blood Cancer J. 2021. PMID: 33980831 Free PMC article. Clinical Trial. No abstract available.
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma.
Mikhael J, Richter J, Vij R, Cole C, Zonder J, Kaufman JL, Bensinger W, Dimopoulos M, Lendvai N, Hari P, Ocio EM, Gasparetto C, Kumar S, Oprea C, Chiron M, Brillac C, Charpentier E, San-Miguel J, Martin T. Mikhael J, et al. Among authors: brillac c. Leukemia. 2020 Dec;34(12):3298-3309. doi: 10.1038/s41375-020-0857-2. Epub 2020 May 14. Leukemia. 2020. PMID: 32409691 Free PMC article. Clinical Trial.
Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.
Rachedi F, Koiwai K, Gaudel-Dedieu N, Sebastien B, Thai HT, Brillac C, Fau JB, Nguyen L, van de Velde H, Veyrat-Follet C, Semiond D. Rachedi F, et al. Among authors: brillac c. CPT Pharmacometrics Syst Pharmacol. 2022 Jun;11(6):766-777. doi: 10.1002/psp4.12789. Epub 2022 Apr 17. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35355430 Free PMC article. Clinical Trial.
PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma.
Koiwai K, El-Cheikh R, Thai HT, Brillac C, Fau JB, Veyrat-Follet C, Risse ML, van de Velde H, Semiond D, Nguyen L. Koiwai K, et al. Among authors: brillac c. CPT Pharmacometrics Syst Pharmacol. 2021 Aug;10(8):928-940. doi: 10.1002/psp4.12666. Epub 2021 Jul 8. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34185964 Free PMC article.
Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer.
Denda T, Sakai D, Hamaguchi T, Sugimoto N, Ura T, Yamazaki K, Fujii H, Kajiwara T, Nakajima TE, Takahashi S, Otsu S, Komatsu Y, Nagashima F, Moriwaki T, Esaki T, Sato T, Itabashi M, Oki E, Sasaki T, Sunaga Y, Ziti-Ljajic S, Brillac C, Yoshino T. Denda T, et al. Among authors: brillac c. Cancer Sci. 2019 Mar;110(3):1032-1043. doi: 10.1111/cas.13943. Epub 2019 Feb 22. Cancer Sci. 2019. PMID: 30657223 Free PMC article. Clinical Trial.